Measles, Mumps, and Rubella (MMR) Vaccine
The measles, mumps, and rubella vaccine is recommended for children 12 months to 12 years old. It is a single shot, often given at the same doctor visit as the varicella (chickenpox) vaccine.
There is one MMR vaccine, M-M-R II, licensed in the United States.
The safety record of the MMR vaccine is good. Most children who get the vaccine do not have any problems. As with all medicine, some side effects – usually very minor – can happen. The MMR vaccine sometimes causes pain where the shot is given, fever, a mild rash, or swelling of the neck or cheek. On very rare occasions, the vaccine’s ingredients cause severe (anaphylactic) allergic reactions.
In addition, the MMR vaccine has been linked with a very small risk of febrile seizures (seizures or jerking caused by fever). This happens most often in children between 12-23 months old. Febrile seizures can happen any time a child gets sick and has a fever. Most happen in children 14-18 months old. Because the risk of febrile seizures increases as infants get older, it is recommended that children get vaccinated as soon as recommended (12-15 months old for the MMR vaccine).
Other rare risks linked with MMR vaccine include joint pain, temporary arthritis, and immune thrombocytopenic purpura (ITP), a disorder that decreases the blood platelet count.
CDC and FDA monitor the safety of vaccines after they are licensed. Any problems detected with these vaccines will be reported to health officials, health care providers, and the public. Needed action will be taken to ensure the public’s health and safety.
CDC uses three systems to monitor vaccine safety:
- The Vaccine Adverse Event Reporting System (VAERS)– an early warning system that helps CDC and FDA monitor problems following vaccination. Anyone can report suspected vaccine reactions and issues to VAERS.
- The Vaccine Safety Datalink (VSD) – a collaboration between CDC and several health care organizations that allows ongoing monitoring and proactive searches of vaccine-related data.
- The Clinical Immunization Safety Assessment (CISA) - a partnership between CDC and several medical centers that conduct clinical research on vaccine-associated health risks in certain groups of people.
- Two recent studies indicate that for every 10,000 children who get their first MMR and varicella vaccines as separate shots when they are 12-23 months old, about 4 will have a febrile seizure during the 5-12 days following vaccination. Children of the same age who get the combined measles, mumps, rubella and varicella (MMRV) vaccine as their first vaccine against these diseases are twice as likely to have a febrile seizure during the same time period.
- Studies have shown that for children younger than 7 years old, there is a small increased risk of febrile seizures approximately 8 to14 days after the MMR shot; this happens in about 1 in 3,000-4,000 children.
- Immune thrombocytopenic purpura (ITP) is a disorder that decreases the body’s ability to stop bleeding. It can happen after both natural measles infection as well as after receipt of MMR vaccine. It is usually not life threating, however; treatment can include blood transfusion . The risk of ITP has been shown to be increased in the six weeks following an MMR vaccine, with one study estimating 1 case per 40,000 vaccinated children.
- Joint pain is linked with the rubella portion of MMR vaccine. Joint pain and temporary arthritis happen more often after MMR vaccination in adults than in children. Females after puberty also experience this issue more often than males. Joint pain or stiffness occurs in up to 25% of females past puberty; their symptoms generally begin 1 to 3 weeks after vaccination, are usually mild and last about two days. These symptoms rarely come back.
- Measles inclusion body encephalitis, or severe brain swelling caused by the measles virus, is a complication of getting infected with the wild measles virus. While rare, this almost always happens in patients with low immune systems. The illness usually develops within one year after initial measles infection and has a high death rate. There have been 3 published reports of this complication happening to vaccinated people. In these cases, encephalitis developed between 4 and 9 months after the MMR shot . In one case, the measles vaccine strain was identified as the cause.
- Signs of autism typically appear around the same time that children are recommended to receive the MMR vaccine. Some parents might worry that the vaccine causes autism. Vaccine safety experts, including experts at CDC and the American Academy of Pediatrics (AAP), agree that MMR vaccine is not responsible for increases in the number of children with autism. For more information about vaccines and autism, see: http://www.cdc.gov/vaccinesafety/Concerns/Autism/Index.html
- American Academy of Pediatrics
- American Medical Association
- Autism Society of America
- CDC Studies on Vaccines and Autism [PDF - 316 KB]
- Immunization Action Coalition: MMR vaccine does not cause autism
- MMR Vaccine Information Statement [PDF - 316 KB]
- National Network for Immunization Information
- The MMR Decision Aid from the National Centre for Immunisation Research & Surveillance, Australia
Baram TZ, Gonzalez-Gomez I, Xie ZD, et al. Subacute sclerosing panencephalitis in an infant: diagnostic role of viral genome analysis. Ann Neurol 1994;36:103-108.
Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Ward JI, Marcy SM, DeStefano F, Chen RT, Immanuel V, Pearson JA, Vadheim CM, Rebolledo V, Christakis D, Benson PJ, Lewis N. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine 2001;345(9):656–661.
Beeler J, Varricchio F, Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 1996;15:88-90.
Bibby AC, Farrell A, Cummins M, Erlewyn-Lajeunesse M. Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura? Arch Dis Child 2008;93:354-355.
Bitnun A, Shannon P, Durward A, et al. Measles inclusion-body encephalitis caused by the vaccine strain of measles virus. [PDF - 703 KB] Clin Infect Dis 1999;29:855-861.
Black S, Shinefield H, Ray P, Lewis E, Chen R, Glasser J, Hadler S, Hardy J, Rhodes P, Swint E, Davis R, Thompson R, Mullooly J, Marcy M, Vadheim C, Ward J, Rastogi S, Wise R. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal 1997;16(5):500–503.
Cooper LZ, Ziring PR, Weiss HJ, Matters BA, Krugman S. Transient arthritis after rubella vaccination. Am J Dis Child 1969;118:218-225.
Davis RL, Kramarz P, Bohlke K, Thompson RS, Mullooly J, Black S, Shinefield H, Ward J, Marcy M, Eriksen E, Lewis N, DeStefano F, Chen R. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the vaccine safety datalink project. Archives of Pediatrics and Adolescent Medicine 2001;155(3):354–359.
DeStefano F, Chen RT. Negative association between MMR and autism. [Commentary] Lancet 1999;353(9169):1987–1988.
Dudgeon JA. Congenital rubella. J Pediatr. 1975 Dec;87(6 Pt 2):1078-86.
Dudgeon JA, Marshall WC, Peckham CS. Rubella vaccine trials in adults and children. Comparison of three attenuated vaccines. Am J Dis Child 1969;118:237-243.
France EK, Glanz J, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008;121:e687-692.
Marshall WC, Peckham CS, Darby CP, Dudgeon JA, Hawkins GT. Further studies with rubella vaccines in adults and children. Practitioner 1971;207:632-638.
Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001;84:227-229.
Mustafa MM, Weitman SD, Winick NJ, et al. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. [PDF - 959 KB] Clin Infect Dis 1993;16:654-660.
Polk BF, Modlin JF, White JA, DeGirolami PC. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982;115:19-25.